Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 98156403 | 9815640 | 3 | F | 20101207 | 20160706 | 20140114 | 20160812 | EXP | US-ROCHE-769962 | ROCHE | 62.00 | YR | M | Y | 89.40000 | KG | 20160812 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 98156403 | 9815640 | 1 | PS | Vismodegib | VISMODEGIB | 1 | Oral | 150 MG, QD, LAST DOSE:02/JAN/2011 | NOT REPORTED | 203388 | 3000 | MG | CAPSULE | QD | |||||
| 98156403 | 9815640 | 2 | SS | Vismodegib | VISMODEGIB | 1 | Oral | NOT REPORTED | 203388 | 2850 | MG | CAPSULE | QD | ||||||
| 98156403 | 9815640 | 3 | SS | Vismodegib | VISMODEGIB | 1 | Oral | NOT REPORTED | 203388 | 3150 | MG | CAPSULE | QD | ||||||
| 98156403 | 9815640 | 4 | SS | Vismodegib | VISMODEGIB | 1 | Oral | NOT REPORTED | 203388 | 3150 | MG | CAPSULE | QD | ||||||
| 98156403 | 9815640 | 5 | SS | Vismodegib | VISMODEGIB | 1 | Oral | NOT REPORTED | 203388 | 3150 | MG | CAPSULE | QD | ||||||
| 98156403 | 9815640 | 6 | SS | Vismodegib | VISMODEGIB | 1 | Oral | NOT REPORTED | 203388 | 3150 | MG | CAPSULE | QD | ||||||
| 98156403 | 9815640 | 7 | SS | Vismodegib | VISMODEGIB | 1 | Oral | NOT REPORTED | 203388 | 3150 | MG | CAPSULE | QD | ||||||
| 98156403 | 9815640 | 8 | SS | Vismodegib | VISMODEGIB | 1 | Oral | NOT REPORTED | 203388 | 3300 | MG | CAPSULE | QD | ||||||
| 98156403 | 9815640 | 9 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Intravenous (not otherwise specified) | OVER 2 HOURS ON DAY 1-3 IN 21 DAY CYCLE, LAST DOSE: 16/DEC/2010 | 0 | ||||||||||
| 98156403 | 9815640 | 10 | SS | CISPLATIN. | CISPLATIN | 1 | Intravenous (not otherwise specified) | OVER 2 HOURS ON DAY 1 IN 21 DAY CYCLE, LAST DOSE : 14/DEC/2010 | 0 | 75 | MG/M**2 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 98156403 | 9815640 | 1 | Small cell lung cancer |
| 98156403 | 9815640 | 9 | Small cell lung cancer |
| 98156403 | 9815640 | 10 | Small cell lung cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 98156403 | 9815640 | OT |
| 98156403 | 9815640 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 98156403 | 9815640 | Constipation | |
| 98156403 | 9815640 | Hyponatraemia | |
| 98156403 | 9815640 | Hypophosphataemia | |
| 98156403 | 9815640 | Neutrophil count decreased | |
| 98156403 | 9815640 | White blood cell count decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 98156403 | 9815640 | 10 | 20101121 | 0 |